Here’s the lowdown

The DEA on Wednesday is expected to finalize the previously suggested Schedule II status for Syndros, the FDA-approved liquid dronabinol drug developed by Insys Therapeutics, the Chandler, Ariz.-based pharmaceutical company that last year donated to a campaign opposing marijuana legalization and last month saw its founder arrested on fraud and racketeering charges.

More at  http://www.thecannabist.co/2017/11/21/dea-syndros-synthetic-thc-insys-schedule-ii/92862/